From: tktrimbath | 6/30/2013 6:28:13 PM | | | | INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.
Geron GERN (market cap was $0.184B is $0.196B) Geron is a high tech biotech that may yet revolutionize critical care treatment of severe ailments like cancer. Their initial list of impressive technologies has been reduced primarily to one: telomerase. Control telomerase and control cell death and growth, which means control cancer and destructive diseases. Even one success would probably make Geron into a multi-billion dollar company. (Though DNDN's history shows a disconnect between medical success and investment success, so far.) At this point that would probably be a ten-fold increase in stock price. Unfortunately, bold claims require bold proof, and the FDA moves slowly when faced with bold measures. Geron is in Phase II clinical trials, which means FDA approval is probably years away unless a compassionate case can be made. They've been at this for over twenty years. An optimist will say they're due. A pessimist will say they won't make it. I'll hold because their bold claims have good reason to come through. Besides, I may have enough stock if they succeed.
DISCLOSURE LTBH since 1999 and continuing to hold. My finances are strained by similar stories throughout what I thought was a diversified portfolio. My house may go into foreclosure, and additional sacrifices may be made, including selling stocks I'd rather hold, or even buy. So, if I sell, it will probably be because I have to, not because I want to. (I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.wordpress.com |
| Geron Corp. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
From: Savant | 8/6/2013 3:04:19 AM | | | | BioTime CEO Dr. Michael West to Present at the Case Western Reserve University 6th Annual Regenerative Medicine Business Education Course ALAMEDA, Calif.--(BUSINESS WIRE)--July 16, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will present today at the Case Western Reserve University in the meeting "The Business of Regenerative Medicine: From Stem Cells to the Market Place" in Cleveland, Ohio. Dr. West's presentation titled "Embryomics: Commercial Opportunities in the Increasing Complex Biology of Pluripotency" is scheduled for 11:00 a.m. EDT. Dr. West will describe new data relating the company's PureStem(TM) technology and cell lines potentially useful in the treatment of Alzheimer's disease and for Alzheimer's disease research and will soon be made available for sale to the research community. The presentation is available on BioTime's website at www.biotimeinc.com/scientific-presentations. A discussion of the results presented in today's meeting is also discussed by Dr. West in his weekly video update available for viewing at www.biotimeinc.com/video-series/. About BioTime, Inc. BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary PureStem(TM) cell lines, HyStem(R) hydrogels, culture media, and differentiation kits. BioTime is developing Renevia(TM) (formerly known as HyStem(R) -Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx(TM) currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards(R) , the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery(TM) database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap Sciences also markets BioTime research products and PanDaTox, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a new subsidiary being used to acquire the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine. BioTime's lead product, Hextend(R) , is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at www.biotimeinc.com. |
| Geron Corp. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
To: Savant who wrote (3364) | 8/6/2013 3:05:37 AM | From: Savant | | | BioTime Subsidiary LifeMap Sciences Announces Publication of Research Report Describing LifeMap Discovery(TM) ALAMEDA, Calif.--(BUSINESS WIRE)--July 18, 2013-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that the LifeMap Discovery(TM) product has been documented in a published paper authored by LifeMap Sciences' research and development team. LifeMap Discovery(TM) (available as of November 2012 via discovery.lifemapsc.com is the first "roadmap" directing scientists through the many hundreds of branch points in the stems of the tree of human cellular life. It also merges experimental knowledge on stem cell biology and regenerative medicine, striving to aid researchers in the quest to produce functional cells capable of regenerating particular tissues in the body, for the treatment of a variety of degenerative diseases. LifeMap Discovery(TM) is a key component of LifeMap's therapeutic discovery collaboration with BioTime and is utilized in conjunction with LifeMap's proprietary bioinformatics tools to select the PureStem(TM) cells that are most likely to be useful in developing cell-based regenerative medicine therapies for a wide range of diseases. The publication titled "LifeMap Discovery(TM): The embryonic development, stem cells, and regenerative medicine research portal" in the open access peer-reviewed journal PLOS ONE can be viewed via the link dx.plos.org. The publication describes the scientific and technological foundations of LifeMap Discovery(TM), the first road map of embryonic development on a cellular level. Key features that are described in the publication include the following: Embryonic development tree LifeMap Discovery(TM) displays more than 1,400 cell types and anatomical structures of the developing embryo and the cellular differentiation that occurs during mammalian embryonic development, branching from the zygote to the progenitor cells and terminating at the mature cells. It covers developmental paths of various types of cells, including blood, endothelium, motor neurons, bone, cartilage and many more. Stem cell differentiation protocols LifeMap Discovery(TM) provides more than 100 protocols used to induce differentiation of various embryonic and progenitor cells and of induced pluripotent stem cells into various cell types (for example, a protocol for derivation of motor neuron-like cells). Each protocol is displayed in a "card" that contains an informative and interactive viewer, sketching the protocol in a stepwise fashion. Regenerative medicine LifeMap Discovery(TM) provides a wealth of information on diseases which represent potential targets for cell-based therapeutic approaches and medically relevant information relating to regenerative medicine. It also provides cell-based therapy approaches that apply cultured stem cells towards treatment of degenerative diseases, via replacement of damaged cells or tissues, and/or stimulation of the body's natural repair mechanisms. Gene expression and signaling Cells and anatomical compartments of the developing embryo are characterized by specific gene expression profiles and selective markers, as well as by signaling molecules that participate in pathways which guide embryonic development. LifeMap Discovery(TM) provides this molecular information for various cell types as well as for cultured stem, progenitor and primary cells. It also provides a centralized means of identifying cell types throughout in vivo embryonic development or in vitro stem cell differentiation procedures, based on specific gene expression profiles. "The sophisticated detail in the LifeMap Discovery(TM) database is a reflection of a movement underway in regenerative medicine toward a higher definition of cell types in research and therapy," said Dr. Michael West, CEO of BioTime. "We believe the database will not only bring more traffic to the LifeMap database suite, but will also be the backbone for moving this increasingly complex field toward clinical application." "The publication describing LifeMap Discovery(TM) in a leading journal in its field is a validation of the scientific merits of this leading edge state-of-the-art product," stated David Warshawsky, Ph.D., President and CEO of LifeMap Sciences. "Our team is dedicated to continuing to enhance LifeMap Discovery(TM) and we are delighted to see the rapid growth of use by the global research community, already several tens of thousands of users. We are eager to see the impact that this remarkable resource will have in the transformative field of regenerative medicine." About LifeMap Sciences, Inc. LifeMap Sciences' (www.lifemapsc.com) core technology and business is based on the LifeMap Integrated Biomedical Knowledgebase, the discovery platform for biomedical and stem cell research. This web-based platform includes GeneCards(R) , the leading human gene compendium; LifeMap Discovery(TM), the embryonic development, stem cell research and regenerative medicine compendium; and MalaCards, the human disease compendium. According to Google Analytics, the sites have generated more than 2,000,000 unique visitors with more than 13,000,000 page views, from more than 3,000 universities, institutions and biomedical companies in the past 12 months. Via LifeMap BioReagents(TM), LifeMap offers leading edge reagents to researchers in academia, research hospitals, and biotech and pharma companies. LifeMap is BioTime's principal marketing subsidiary for research products, including PureStem(TM) human progenitor cells, PureStem(TM) packages, clinical and research grade human embryonic stem cell (hES) lines, culture media, and cell differentiation kits. The eCommerce portal also offers select recombinant proteins, including growth factors, signaling molecules, differentiation factors, cytokines and chemokines that complement BioTime research product lines. In therapeutic discovery collaboration with BioTime, LifeMap's scientists utilize the Integrated Biomedical Knowledgebase to aid in the development of BioTime's proprietary library of more than 200 PureStem(TM) human progenitor cell types into products for the treatment of human diseases, especially degenerative diseases that might be treatable with cell replacement therapies. A bioinformatics platform developed by LifeMap is used to select the PureStem(TM) cells that are most likely to be useful in developing cell-based regenerative medicine therapies for a wide range of diseases. |
| Geron Corp. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
From: Savant | 8/6/2013 3:12:36 AM | | | | BioTime's Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker - FSIP1 is one component of a panel of markers comprising PanC-Dx(TM) , a blood-based cancer screen - ALAMEDA, Calif.--(BUSINESS WIRE)--August 05, 2013-- BioTime, Inc. (NYSE MKT: BTX) and BioTime's subsidiary OncoCyte Corporation today announced the publication of a scientific report on the gene FSIP1 and its potential as a marker for breast cancer. The paper, published in the peer-reviewed journal Biomarkers in Medicine and available online today, describes the microarray-based approach used to identify FSIP1 as a breast cancer biomarker with significantly elevated expression in breast tumors expressing the estrogen receptor, which represents 70-80% of all breast cancers. In addition to elevated gene expression, FSIP1 protein was also expressed within tumors at significant levels whereas little to no expression was found in most normal tissues, including healthy breast tissue. Combined, these findings lay the foundation for novel diagnostic and therapeutic strategies, including the measurement of FSIP1 in the blood as a screen for the presence of cancer, as well as targeting of FSIP1 as an antigen in cancer immunotherapy approaches. Based on large unmet need, market size, and data generated thus far from patient sample screening, OncoCyte is initially focusing its efforts on identifying biomarkers that may be used to detect and monitor breast and bladder cancers. OncoCyte has been developing, characterizing, and manufacturing monoclonal antibodies for use in detecting breast cancer, in preparation for the initiation of the first clinical study of PanC-Dx(TM) and is currently working with a select group of cancer researchers to finalize a study protocol for submission to the institutional review boards of the study sites. If clinical trials are successful, OncoCyte intends to launch PanC-Dx(TM) as an in vitro diagnostic (IVD) in Europe before seeking FDA approval required to market PanC-Dx(TM) in the United States. About BioTime, Inc. BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary PureStem(TM) cell lines, HyStem(R) hydrogels, culture media, and differentiation kits. BioTime is developing Renevia(TM) (formerly known as HyStem(R)-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx(TM) currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards(R), the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery(TM) database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap Sciences also markets BioTime research products and PanDaTox, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a new subsidiary being used to acquire the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine. BioTime's lead product, Hextend(R), is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at www.biotimeinc.com. About OncoCyte Corporation OncoCyte Corporation is a majority-owned subsidiary of BioTime, Inc. OncoCyte's mission is to develop novel products for the diagnosis and treatment of cancer in order to improve both the quality and length of life of cancer patients. OncoCyte's molecular diagnostics division is developing products for earlier detection of a variety of cancers. In addition to its diagnostic product line, OncoCyte is developing cellular therapies to treat cancer based on the unique biology of vascular precursor cells. The goal of OncoCyte's therapeutic research efforts is to derive vascular cells that can be engineered to deliver a toxic payload to the developing blood vessels of a malignant tumor to destroy the tumor without killing nearby normal tissues in the body. Additional information on OncoCyte can be found on the web at www.oncocyte.com Forward-Looking Statements Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements. To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: news.biotimeinc.com CONTACT: BioTime, Inc. Robert Peabody Sr. VP & CFO 510-521-3390, ext 302 rpeabody@biotimemail.com or Judith Segall 510-521-3390, ext 301 jsegall@biotimemail.com |
| Geron Corp. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
From: Savant | 8/8/2013 7:47:33 PM | | | | Geron reports EPS in-line, misses on revs | Reports Q2 (Jun) GAAP loss of $0.07 per share, in-line with the Capital IQ Consensus Estimate consensus of ($0.07); revenues fell 13.8% year/year to $0.11 mln vs the $0.50 mln consensus. |
| Geron Corp. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
To: tktrimbath who wrote (3371) | 8/9/2013 9:57:22 PM | From: Savant | | | Report... Conference Call
At 4:30 p.m. EDT on August 8, 2013, Geron's management will host a conference call to discuss the company's second quarter results and events.
Participants can access the conference call via telephone by dialing 866-510-0712 (U.S.); 617-597-5380 (international). The passcode is 40043183. A live audio-only webcast is also available at http://edge.media-server.com/m/p/ckj8h4oa/lan/en. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through September 9, 2013. |
| Geron Corp. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |